Overview

Study of Continuous OSI-906 Dosing

Status:
Completed

Trial end date:
2012-03-19

Target enrollment:

Participant gender:

Summary

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc